Alto Neuroscience, Inc. $ANRO Shares Sold by AWM Investment Company Inc.

AWM Investment Company Inc. trimmed its stake in shares of Alto Neuroscience, Inc. (NYSE:ANRO) by 68.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 280,483 shares of the company’s stock after selling 621,501 shares during the period. AWM Investment Company Inc. owned about 1.04% of Alto Neuroscience worth $617,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. AlphaCore Capital LLC raised its holdings in Alto Neuroscience by 100.0% during the 2nd quarter. AlphaCore Capital LLC now owns 20,000 shares of the company’s stock worth $44,000 after buying an additional 10,000 shares during the period. Bank of Montreal Can acquired a new position in shares of Alto Neuroscience in the second quarter worth about $25,000. Ground Swell Capital LLC purchased a new position in shares of Alto Neuroscience in the second quarter worth approximately $27,000. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of Alto Neuroscience during the second quarter valued at approximately $33,000. Finally, Armistice Capital LLC raised its holdings in shares of Alto Neuroscience by 1.5% during the second quarter. Armistice Capital LLC now owns 1,624,000 shares of the company’s stock valued at $3,573,000 after acquiring an additional 24,000 shares during the period.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on ANRO. Jefferies Financial Group lifted their price objective on shares of Alto Neuroscience from $15.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, November 12th. Robert W. Baird raised their target price on Alto Neuroscience from $16.00 to $22.00 and gave the stock an “outperform” rating in a research report on Thursday, November 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Alto Neuroscience in a research report on Wednesday, October 8th. Chardan Capital raised Alto Neuroscience to a “strong-buy” rating in a research note on Wednesday, November 19th. Finally, BTIG Research began coverage on Alto Neuroscience in a research report on Monday, November 17th. They set a “buy” rating and a $27.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $23.83.

Alto Neuroscience Stock Performance

Shares of ANRO stock opened at $15.14 on Friday. Alto Neuroscience, Inc. has a fifty-two week low of $1.60 and a fifty-two week high of $16.49. The stock’s 50-day moving average is $11.61 and its two-hundred day moving average is $6.08. The company has a debt-to-equity ratio of 0.20, a current ratio of 15.42 and a quick ratio of 15.42. The firm has a market cap of $470.37 million, a P/E ratio of -6.61 and a beta of 2.95.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.66) by $0.14. Analysts predict that Alto Neuroscience, Inc. will post -2.54 earnings per share for the current fiscal year.

About Alto Neuroscience

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.